PHARMAC decision-making on new medicines. A case study
Author:
Open Access
- 13 April 2022
- journal article
- research article
- Published by CSIRO Publishing in Journal of Primary Health Care
- Vol. 14 (1) , 4-5
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medicationsJournal of Primary Health Care, 2022
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyBMJ, 2020
- Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New ZealandSeminars in Oncology, 2016
- "Tough but fair"? The active management of the New Zealand drug benefits scheme by an independent Crown agencyAustralian Health Review, 2004